{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T14:17:17.193130+00:00","company":{"ticker":"CYPH","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC."},"pagination":{"limit":100,"returned":45,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"CoinXit Ltd.","detail":"other","count":2,"first_seen":"2025-12-30T23:59:59+00:00","last_seen":"2025-12-30T23:59:59+00:00","evidence_fact_ids":[36822,36823]},{"display_name":"BeiGene, Ltd.","detail":"other","count":1,"first_seen":"2023-03-16T23:59:59+00:00","last_seen":"2023-03-16T23:59:59+00:00","evidence_fact_ids":[171265]},{"display_name":"Flame","detail":"merger","count":1,"first_seen":"2023-01-23T23:59:59+00:00","last_seen":"2023-01-23T23:59:59+00:00","evidence_fact_ids":[184997]},{"display_name":"HealthCare Ventures IX, L.P. and HealthCare Ventures VIII Liquidating Trust","detail":"merger","count":1,"first_seen":"2023-01-23T23:59:59+00:00","last_seen":"2023-01-23T23:59:59+00:00","evidence_fact_ids":[184998]},{"display_name":"those stockholders of Flame that become parties","detail":"other","count":1,"first_seen":"2023-01-23T23:59:59+00:00","last_seen":"2023-01-23T23:59:59+00:00","evidence_fact_ids":[184999]}],"ma_counterparty":[{"display_name":"Flame Biosciences, Inc.","detail":"acquisition","count":2,"first_seen":"2023-01-23T23:59:59+00:00","last_seen":"2023-03-24T23:59:59+00:00","evidence_fact_ids":[169428,185001]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"971e05373e6f09839d752c7a1c27111b2ff4e9d6","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2026-06-22T20:05:23+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-18","outcome":"passed","proposal_text":"Ratification of appointment of EisnerAmper LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"110,376","votes_against":"1,513,757","votes_for":"51,710,093","votes_withheld":null}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered public accounting firm at the 2026-06-18 meeting.","evidence_excerpt":"The appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Votes For Votes Against Votes Abstaining 51,710,093 1,513,757 110,376","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-076364","anchor_url":"https://secwatch.observer/filing/0001104659-26-076364#claim-971e05373e6f09839d752c7a1c27111b2ff4e9d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926076364/0001104659-26-076364-index.htm"},{"fact_type":"shareholder_vote","fact_key":"524b6201b0119d5a97a893f777c02f6afbbe58e7","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2026-06-22T20:05:23+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-18","outcome":"passed","proposal_text":"Advisory vote on executive compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"27,706,780","subject":null,"votes_abstain":"658,610","votes_against":"4,286,839","votes_for":"20,681,997","votes_withheld":null}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Advisory vote on executive compensation of named executive officers at the 2026-06-18 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the executive compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstaining Broker Non-Votes 20,681,997 4,286,839 658,610 27,706,780","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-076364","anchor_url":"https://secwatch.observer/filing/0001104659-26-076364#claim-524b6201b0119d5a97a893f777c02f6afbbe58e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926076364/0001104659-26-076364-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f85058fdd0a7e1f86e79e2af0201c1b6a3f9443f","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2026-06-22T20:05:23+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-18","outcome":"passed","proposal_text":"Election of Class III directors","proposal_type":"director_election","results":[{"broker_non_votes":"27,706,780","subject":"Will McEvoy","votes_abstain":null,"votes_against":null,"votes_for":"24,927,307","votes_withheld":"700,139"},{"broker_non_votes":"27,706,780","subject":"Nissim Mashiach","votes_abstain":null,"votes_against":null,"votes_for":"22,174,332","votes_withheld":"3,453,114"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Election of Class III directors at the 2026-06-18 meeting.","evidence_excerpt":"The following director nominees were elected to serve as Class III directors until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Will McEvoy 24,927,307 700,139 27,706,780 Nissim Mashiach 22,174,332 3,453,114 27,706,780","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-076364","anchor_url":"https://secwatch.observer/filing/0001104659-26-076364#claim-f85058fdd0a7e1f86e79e2af0201c1b6a3f9443f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926076364/0001104659-26-076364-index.htm"},{"fact_type":"earnings_release","fact_key":"c6acda4bf08879bfd35fd678a37c312b43334bd3","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2026-05-14T11:10:29+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $77.2 million for the first quarter 2026","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-14","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2026 results: net income Net loss was $77.2 million for the first quarter 2026.","evidence_excerpt":"Cypherpunk Technologies Inc., (Nasdaq: CYPH) (\"Cypherpunk\"), today reported financial results for the first quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-060686","anchor_url":"https://secwatch.observer/filing/0001104659-26-060686#claim-c6acda4bf08879bfd35fd678a37c312b43334bd3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926060686/0001104659-26-060686-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"cc650d596da431a4405bcdbefbd3760d0d981d3a","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2026-03-09T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-08-31","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 per share","notice_date":"2026-08-31","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"f The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that,\nfor the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00\nper share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”).\nThe Closing Bid Price Deficiency Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading\nof the Company’s shares of common stock on The Nasdaq Capital Market. The Company\nhas 180 days, or until August 31, 2026, to regain c","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-025194","anchor_url":"https://secwatch.observer/filing/0001104659-26-025194#claim-cc650d596da431a4405bcdbefbd3760d0d981d3a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926025194/0001104659-26-025194-index.htm"},{"fact_type":"material_agreement","fact_key":"f51ca8ccb9f57c3a77d7ae7f1331951883c3fa21","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-12-30T23:59:59+00:00","payload":{"action":"termination","agreement_name":"November 2025 CoinXit RSUs Agreement","agreement_type":"other","counterparty":"CoinXit Ltd.","effective_date":"2025-12-23","item_codes_triggered":["1.01","1.02"],"value_text":"Termination and cancellation of 2,411,700 RSUs"},"claim":"CYPHERPUNK TECHNOLOGIES INC. terminated November 2025 CoinXit RSUs Agreement with CoinXit Ltd. valued at Termination and cancellation of 2,411,700 RSUs (effective 2025-12-23).","evidence_excerpt":"Pursuant to the December 2025 CoinXit RSUs Agreement, the Company and CoinXit also agreed (i) to terminate and cancel the November 2025 CoinXit RSUs issued pursuant to the November 2025 CoinXit RSUs Agreement, and (ii) to treat the grant by the Company to CoinXit of the December 2025 CoinXit RSUs as satisfying in full all of the Company’s obligations under the Consulting Agreement to grant CoinXit 5,448,157 RSUs under the Company’s equity incentive plans.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-125224","anchor_url":"https://secwatch.observer/filing/0001104659-25-125224#claim-f51ca8ccb9f57c3a77d7ae7f1331951883c3fa21","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925125224/0001104659-25-125224-index.htm"},{"fact_type":"material_agreement","fact_key":"f5900aa6fb2c9f0077ab0546f439ca91ddafdb6e","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-12-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"December 2025 CoinXit RSUs Agreement","agreement_type":"other","counterparty":"CoinXit Ltd.","effective_date":"2025-12-23","item_codes_triggered":["1.01","1.02"],"value_text":"Grant of 5,448,157 RSUs"},"claim":"CYPHERPUNK TECHNOLOGIES INC. entered into December 2025 CoinXit RSUs Agreement with CoinXit Ltd. valued at Grant of 5,448,157 RSUs (effective 2025-12-23).","evidence_excerpt":"On December 23, 2025, the Compensation Committee of the Board approved the grant under the Company’s 2025 Equity Incentive Plan (the “2025 Plan”) of 5,448,157 RSUs to CoinXit (the “December 2025 CoinXit RSUs”), pursuant to a Restricted Stock Unit Grant Agreement, dated December 23, 2025 (the “December 2025 CoinXit RSUs Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-125224","anchor_url":"https://secwatch.observer/filing/0001104659-25-125224#claim-f5900aa6fb2c9f0077ab0546f439ca91ddafdb6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925125224/0001104659-25-125224-index.htm"},{"fact_type":"governance_change","fact_key":"9a11ce69cfb5221444a95081a6db7c32ccb7ecc5","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-12-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-15","item_codes_triggered":["5.03"],"summary_text":"Stockholders approved and the Company filed a Certificate of Amendment to increase authorized shares from 250,000,000 to 500,000,000 and add clarifying language regarding DGCL Section 242."},"claim":"CYPHERPUNK TECHNOLOGIES INC.: Stockholders approved and the Company filed a Certificate of Amendment to increase authorized shares from 250,000,000 to 500,000,000 and add clarifying language regarding DGCL Section 242 (effective 2025-12-15).","evidence_excerpt":"At the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Charter”) to (i) increase the total number of shares that the Company is authorized to issue from 250,000,000 shares to 500,000,000 shares, of which 490,000,000 shares are designated as Common Stock, and 10,000,000 shares are designated as preferred stock, par value $0.001 per share, and (ii) include clarifying language regarding the applicability of recently amended provisions of Section 242 of the General Corporation Law of the State of Delaware ((i) and (ii) collectively, the “Charter Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-121566","anchor_url":"https://secwatch.observer/filing/0001104659-25-121566#claim-9a11ce69cfb5221444a95081a6db7c32ccb7ecc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925121566/0001104659-25-121566-index.htm"},{"fact_type":"equity_issuance","fact_key":"3de43c8178f64f796a287560d31f258b96d5a10c","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-10-09T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"offering price of $0.51964 per Pre-Funded Warrant","effective_date":"2025-10-08","item_codes_triggered":["3.02"],"purchaser":"investors named therein","security_type":"warrant","shares_text":"up to an aggregate of 80,768,504 shares of Common Stock"},"claim":"CYPHERPUNK TECHNOLOGIES INC. issued up to an aggregate of 80,768,504 shares of Common Stock of warrant to investors named therein for offering price of $0.51964 per Pre-Funded Warrant.","evidence_excerpt":"”) of (i) an aggregate of 15,212,311 shares (the “ Shares ”) of common stock of the Company, par value\n$0.001 per share (the “ Common Stock ”), at an offering price of $0.52064 per share, (ii) pre-funded warrants (the “ Pre-Funded\nWarrants ”) to purchase up to an aggregate of 80,768,504 shares of Common Stock (the “ Pre-Funded Warrant Shares ”)\nat an","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-098082","anchor_url":"https://secwatch.observer/filing/0001104659-25-098082#claim-3de43c8178f64f796a287560d31f258b96d5a10c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925098082/0001104659-25-098082-index.htm"},{"fact_type":"equity_issuance","fact_key":"e19e8013e4f8b10b3fb54ccea804019cd6593c51","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-10-09T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"exercise price of $0.5335 per Common Warrant Share","effective_date":"2025-10-08","item_codes_triggered":["3.02"],"purchaser":"investors named therein","security_type":"warrant","shares_text":"up to an aggregate of 71,985,605 shares of Common Stock"},"claim":"CYPHERPUNK TECHNOLOGIES INC. issued up to an aggregate of 71,985,605 shares of Common Stock of warrant to investors named therein for exercise price of $0.5335 per Common Warrant Share.","evidence_excerpt":"”) to purchase up to an aggregate of 71,985,605 shares of Common Stock (the “ Common\nWarrant Shares ”), each exercisable for one share of Common Stock at the exercise price of $0.5335 per Common Warrant Share. The Private Placement closed on October 8, 2025\n(the “ Closing Date ”). The aggregate gross proceeds of the Private Placement were approximately USD","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-098082","anchor_url":"https://secwatch.observer/filing/0001104659-25-098082#claim-e19e8013e4f8b10b3fb54ccea804019cd6593c51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925098082/0001104659-25-098082-index.htm"},{"fact_type":"equity_issuance","fact_key":"c1895367337de98542d2577bb9e478bc1b8886b4","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-10-09T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$0.52064 per share","effective_date":"2025-10-08","item_codes_triggered":["3.02"],"purchaser":"investors named therein","security_type":"common_stock","shares_text":"15,212,311 shares"},"claim":"CYPHERPUNK TECHNOLOGIES INC. issued 15,212,311 shares of common stock to investors named therein for $0.52064 per share.","evidence_excerpt":"”) of (i) an aggregate of 15,212,311 shares (the “ Shares ”) of common stock of the Company, par value\n$0.001 per share (the “ Common Stock ”), at an offering price of $0.52064 per share, (ii) pre-funded warrants (the “ Pre-Funded\nWarrants ”) to purchase up to an aggregate of 80,768,504 shares of Common Stock (the “ Pre-Funded Warrant Shares ”)\nat an","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-098082","anchor_url":"https://secwatch.observer/filing/0001104659-25-098082#claim-c1895367337de98542d2577bb9e478bc1b8886b4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925098082/0001104659-25-098082-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"ba7d0e2c8b8b1997acac54024cd3a2bc1047b769","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-09-11T23:59:59+00:00","payload":{"company_response":"intention to cure the deficiency during the second compliance period by effecting a reverse split, if necessary.","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":true,"minimum_requirement":"$1.00 per share","notice_date":"2025-09-08","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"rsuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Company had 180 days, or until Sept","reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"CYPHERPUNK TECHNOLOGIES INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"September 8, 2025, to regain compliance with Rule 5550(a)(2) by maintaining\na closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. Additionally, Nasdaq notified the Company\nthat it might be eligible for an additional compliance period of 180 calendar days if, on September 8, 2025, the Company met the continued\nlisting requirement for market value of publicly held shares and all other applicable standards for initial listing on the Nasdaq Capital\nMarket (with the exception of the closing bid price requirement) based on the Company’s then most recent publi","confidence":0.82,"filing_url":"https://secwatch.observer/filing/0001410578-25-002072","anchor_url":"https://secwatch.observer/filing/0001410578-25-002072#claim-ba7d0e2c8b8b1997acac54024cd3a2bc1047b769","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000141057825002072/0001410578-25-002072-index.htm"},{"fact_type":"restructuring_charge","fact_key":"d58a8c4ccce43586e874ac8c68f18e625445788b","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-06-23T23:59:59+00:00","payload":{"affected_area":"the Company's research and development activities, including the Company's sirexatamab and FL-501 development programs","charge_text":"approximately $3.2 million","effective_date":"2025-06-30","event_type":"restructuring","headcount_text":"approximately 75% of the Company's current workforce","item_codes_triggered":["2.05"]},"claim":"CYPHERPUNK TECHNOLOGIES INC. announced a restructuring with charges of approximately $3.2 million affecting the Company's research and development activities, including the Company's sirexatamab and FL-501 development programs (approximately 75% of the Company's current workforce).","evidence_excerpt":"Due to current market conditions and the financial position of Leap Therapeutics, Inc. (the “Company”), the Company’s Board of Directors has approved a series of measures to conserve cash and reduce operating costs, including (i) the completion of the DeFianCe clinical trial and the wind-down of the Company’s research and development activities, including the Company’s sirexatamab and FL-501 development programs, and (ii) a reduction in force that will impact approximately 75% of the Company’s current workforce (the “Reduction In Force”) to be implemented in two phases (a) first, on or about June 30, 2025 that will impact the Company’s Chief Operating Officer, and (b) second, on or about July 31, 2025 that will impact the Chief Medical Officer of the Company. The Company estimates that it will incur approximately $3.2 million in costs primarily related to severance payments and related expenses in connection with the Reduction In Force.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-061385","anchor_url":"https://secwatch.observer/filing/0001104659-25-061385#claim-d58a8c4ccce43586e874ac8c68f18e625445788b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925061385/0001104659-25-061385-index.htm"},{"fact_type":"executive_change","fact_key":"0dfe2fb01c","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-06-23T23:59:59+00:00","payload":{"action":"terminated without cause","action_category":"departure","departure_tone":"termination","effective_date":"2025-07-31","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Cyndi Sirard, MD departed as Chief Medical Officer at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"Cyndi Sirard, MD will be terminated without cause from her position as the Company’s Chief Medical Officer, effective on or about July 31, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-061385","anchor_url":"https://secwatch.observer/filing/0001104659-25-061385#claim-0dfe2fb01c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925061385/0001104659-25-061385-index.htm"},{"fact_type":"executive_change","fact_key":"2b91071d53","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-06-23T23:59:59+00:00","payload":{"action":"terminated without cause","action_category":"departure","departure_tone":"termination","effective_date":"2025-06-30","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Augustine Lawlor departed as Chief Operating Officer at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"Augustine Lawlor will be terminated without cause from his position as the Company’s Chief Operating Officer, effective June 30, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-061385","anchor_url":"https://secwatch.observer/filing/0001104659-25-061385#claim-2b91071d53","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925061385/0001104659-25-061385-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c8b6b88ee5ad93018300272fdeff9aa327720a83","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-03-17T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-09-08","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-03-12","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"f The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that,\nfor the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00\nper share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”).\nThe Closing Bid Price Deficiency Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading\nof the Company’s shares of common stock on The Nasdaq Capital Market. The Company\nhas 180 days, or until September 8, 2025, to regain","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-024450","anchor_url":"https://secwatch.observer/filing/0001104659-25-024450#claim-c8b6b88ee5ad93018300272fdeff9aa327720a83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925024450/0001104659-25-024450-index.htm"},{"fact_type":"earnings_release","fact_key":"4844a58f72df9a80af9bac922d337bc3349a4e93","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$13.8 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2024 results: net income $13.8 million.","evidence_excerpt":"Net Loss was $13.8 million for the first quarter 2024, compared to $41.9 million for the same period in 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-060199","anchor_url":"https://secwatch.observer/filing/0001104659-24-060199#claim-4844a58f72df9a80af9bac922d337bc3349a4e93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/0001104659-24-060199-index.htm"},{"fact_type":"material_agreement","fact_key":"1ebde0cd8b4cea83483e91bb0b391cc4639f6e65","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-04-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2024-04-10","item_codes_triggered":["1.01"],"value_text":"approximately $40 million"},"claim":"CYPHERPUNK TECHNOLOGIES INC. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $40 million (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, Leap Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers,” and each, a “Purchaser”) providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company expects to issue and sell to the Purchasers an aggregate of (a) 12,660,993 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price per Share equal to $2.82, and (b) pre-funded warrants, in the form attached to the Securities Purchase Agreement as Exhibit B (the “Pre-Funded Warrants”), to purchase 1,523,404 shares of Common Stock (such shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”), at a purchase price per Pre-Funded Warrant equal to (i) $2.819 (which is equal to the price","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-046108","anchor_url":"https://secwatch.observer/filing/0001104659-24-046108#claim-1ebde0cd8b4cea83483e91bb0b391cc4639f6e65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924046108/0001104659-24-046108-index.htm"},{"fact_type":"earnings_release","fact_key":"1a4b48eda9c28f1382d5eaf55c6293f01ad7b186","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-03-18T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$81.4 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-18","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported the year ended December 31, 2023 results: net income $81.4 million.","evidence_excerpt":"Net Loss was $81.4 million for the year ended December 31, 2023,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-035239","anchor_url":"https://secwatch.observer/filing/0001104659-24-035239#claim-1a4b48eda9c28f1382d5eaf55c6293f01ad7b186","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924035239/0001104659-24-035239-index.htm"},{"fact_type":"earnings_release","fact_key":"57f2c20d5ed4adaa6b51acb89250a414edb83c54","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net Loss was $13.7 million","period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2023 results: net income Net Loss was $13.7 million.","evidence_excerpt":"Net Loss was $13.7 million for the third quarter 2023, compared to $15.1 million for the same period in 2022.","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001104659-23-116657","anchor_url":"https://secwatch.observer/filing/0001104659-23-116657#claim-57f2c20d5ed4adaa6b51acb89250a414edb83c54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/0001104659-23-116657-index.htm"},{"fact_type":"earnings_release","fact_key":"4fed69b5ae00ebbf8d10b3c8ed41f64ad7c2237a","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"second quarter ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-090875","anchor_url":"https://secwatch.observer/filing/0001104659-23-090875#claim-4fed69b5ae00ebbf8d10b3c8ed41f64ad7c2237a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/0001104659-23-090875-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e284dd88b8823b383f376e386266ad7b8b4bb022","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Amendment to certificate of incorporation to effect reverse stock split","proposal_type":"charter_amendment","results":[{"broker_non_votes":"23,112,751","subject":null,"votes_abstain":"245,852","votes_against":"4,223,712","votes_for":"69,467,604","votes_withheld":"0"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Amendment to certificate of incorporation to effect reverse stock split at the 2023-06-16 meeting.","evidence_excerpt":"The amendment to the Fourth Amended and Restated Certificate of Incorporation to effect a reverse stock split was approved. Votes For Votes Against Votes Abstaining Broker Non-Votes 69,467,604 4,223,712 245,852 23,112,751","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-23-073405","anchor_url":"https://secwatch.observer/filing/0001104659-23-073405#claim-e284dd88b8823b383f376e386266ad7b8b4bb022","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923073405/0001104659-23-073405-index.htm"},{"fact_type":"shareholder_vote","fact_key":"57b94acdb8a2d1274a52dda15a7621331ad84cab","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Approval of issuance of common stock upon conversion of Series X Non-Voting Convertible Preferred Stock","proposal_type":"other","results":[{"broker_non_votes":"22,878,528","subject":null,"votes_abstain":"461,534","votes_against":"2,736,543","votes_for":"54,478,792","votes_withheld":"0"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Approval of issuance of common stock upon conversion of Series X Non-Voting Convertible Preferred Stock at the 2023-06-16 meeting.","evidence_excerpt":"The Company’s stockholders approved the issuance of the Company’s common stock upon the conversion of the Company’s Series X Non-Voting Convertible Preferred Stock (none of the shares of Common Stock represented by proxies or electronic votes at the Meeting that constituted shares of Common Stock issued by the Company to the former stockholders of Flame Biosciences, Inc. pursuant to the Agreement and Plan of Merger, dated as of January 17, 2023 by and among the Company, Fire Merger Sub, Inc., Flame Biosciences LLC, Flame Biosciences, Inc. and the Stockholder Representative, were entitled to vote on this proposal and, accordingly, none of such shares were voted on this proposal and/or counted or taken into account in the voting totals reflected below with respect to this proposal). Votes For Votes Against Votes Abstaining Broker Non-Votes 54,478,792 2,736,543 461,534 22,878,528","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-23-073405","anchor_url":"https://secwatch.observer/filing/0001104659-23-073405#claim-57b94acdb8a2d1274a52dda15a7621331ad84cab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923073405/0001104659-23-073405-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9bf07aaa47a0edb86321104def1e6bba31dbc39f","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Ratification of EisnerAmper LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"26,305,923","votes_against":"1,706,979","votes_for":"69,037,017","votes_withheld":"0"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Ratification of EisnerAmper LLP as independent registered public accounting firm at the 2023-06-16 meeting.","evidence_excerpt":"The appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified. Votes For Votes Against Votes Abstaining 69,037,017 1,706,979 26,305,923","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-23-073405","anchor_url":"https://secwatch.observer/filing/0001104659-23-073405#claim-9bf07aaa47a0edb86321104def1e6bba31dbc39f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923073405/0001104659-23-073405-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d615db1934e0cd851637ed13985fa23d3d898f49","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Amendment to the 2022 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"22,878,528","subject":null,"votes_abstain":"25,209,179","votes_against":"11,214,966","votes_for":"37,747,246","votes_withheld":"0"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Amendment to the 2022 Equity Incentive Plan at the 2023-06-16 meeting.","evidence_excerpt":"The Amendment to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan was approved. Votes For Votes Against Votes Abstaining Broker Non-Votes 37,747,246 11,214,966 25,209,179 22,878,528","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-23-073405","anchor_url":"https://secwatch.observer/filing/0001104659-23-073405#claim-d615db1934e0cd851637ed13985fa23d3d898f49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923073405/0001104659-23-073405-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e233f37ef0080c3e6022805f0da9f1a1eb67b6cc","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Advisory vote on frequency of say-on-pay votes","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"22,878,528","subject":null,"votes_abstain":"22,809,396","votes_against":"0","votes_for":"38,991,427","votes_withheld":"0"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-06-16 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, that future advisory votes on the compensation of the Company’s named executive officers be held every year. Votes For One Year Votes For 2 Years Votes For 3 Years Votes Abstain Broker Non-Votes 38,991,427 1,475,156 10,895,412 22,809,396 22,878,528","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-23-073405","anchor_url":"https://secwatch.observer/filing/0001104659-23-073405#claim-e233f37ef0080c3e6022805f0da9f1a1eb67b6cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923073405/0001104659-23-073405-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f08078e2ec0b1cdef7d06a0a29f0ec3682239213","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Advisory vote on executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"22,878,528","subject":null,"votes_abstain":"25,157,298","votes_against":"4,420,867","votes_for":"44,593,226","votes_withheld":"0"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Advisory vote on executive compensation at the 2023-06-16 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the executive compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstaining Broker Non-Votes 44,593,226 4,420,867 25,157,298 22,878,528","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-23-073405","anchor_url":"https://secwatch.observer/filing/0001104659-23-073405#claim-f08078e2ec0b1cdef7d06a0a29f0ec3682239213","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923073405/0001104659-23-073405-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e33c3a1be083bf2de96637449b1e76272a189342","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Election of Class III directors","proposal_type":"director_election","results":[{"broker_non_votes":"25,488,424","subject":"Joseph Loscalzo","votes_abstain":"29,951,085","votes_against":"0","votes_for":"42,645,725","votes_withheld":"1,574,581"},{"broker_non_votes":"25,488,424","subject":"Nissim Mashiach","votes_abstain":"23,037,162","votes_against":"0","votes_for":"46,931,215","votes_withheld":"1,593,118"},{"broker_non_votes":"25,488,424","subject":"Christopher Mirabelli","votes_abstain":"23,055,905","votes_against":"0","votes_for":"47,007,005","votes_withheld":"1,498,585"}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Election of Class III directors at the 2023-06-16 meeting.","evidence_excerpt":"The following director nominees were elected to serve as Class III directors until the Company’s 2026 annual meeting of stockholders and until their successors are duly elected and qualified. Nominee Votes For Votes Withheld Votes Abstaining Broker Non-Votes Joseph Loscalzo 42,645,725 1,574,581 29,951,085 25,488,424 Nissim Mashiach 46,931,215 1,593,118 23,037,162 25,488,424 Christopher Mirabelli 47,007,005 1,498,585 23,055,905 25,488,424","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-23-073405","anchor_url":"https://secwatch.observer/filing/0001104659-23-073405#claim-e33c3a1be083bf2de96637449b1e76272a189342","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923073405/0001104659-23-073405-index.htm"},{"fact_type":"earnings_release","fact_key":"811ced1db3b4cba29b4bb406ee52768368cbdc45","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net Loss was $41.9 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-15","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2023 results: net income Net Loss was $41.9 million.","evidence_excerpt":"On May 15, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-060130","anchor_url":"https://secwatch.observer/filing/0001104659-23-060130#claim-811ced1db3b4cba29b4bb406ee52768368cbdc45","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/0001104659-23-060130-index.htm"},{"fact_type":"earnings_release","fact_key":"dd2e3e14d80145027bdfa1c9e2207d665a35ae68","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-03-24T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2022","report_date":"2023-03-24","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 24, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-036246","anchor_url":"https://secwatch.observer/filing/0001104659-23-036246#claim-dd2e3e14d80145027bdfa1c9e2207d665a35ae68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/0001104659-23-036246-index.htm"},{"fact_type":"ma_transaction","fact_key":"737a4c4a8057e0c2ea0a80eb651147446a9da052","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-03-24T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-01-23","consideration_text":null,"counterparty":"Flame Biosciences, Inc.","effective_date":"2023-01-23","item_codes_triggered":["2.01"]},"claim":"CYPHERPUNK TECHNOLOGIES INC. completed an acquisition involving Flame Biosciences, Inc. (closed 2023-01-23).","evidence_excerpt":"On January 23, 2023, Leap Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing the Company’s acquisition of Flame Biosciences, Inc., a Delaware corporation, pursuant to an Agreement and Plan of Merger, dated January 17, 2023 (the “Acquisition”).","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001104659-23-036607","anchor_url":"https://secwatch.observer/filing/0001104659-23-036607#claim-737a4c4a8057e0c2ea0a80eb651147446a9da052","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923036607/0001104659-23-036607-index.htm"},{"fact_type":"governance_change","fact_key":"4655560f1f55daa709bdf50e77b1c2197a3f62d3","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-03-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-03-16","item_codes_triggered":["5.03"],"summary_text":"Increased ownership threshold required for special voting stock holder to designate a director from 5% to 9.9%"},"claim":"CYPHERPUNK TECHNOLOGIES INC.: Increased ownership threshold required for special voting stock holder to designate a director from 5% to 9.9% (effective 2023-03-16).","evidence_excerpt":"to provide for an increase in the percentage of outstanding shares of Common Stock of the Company that the sole holder of the Company’s Special Voting Stock, together with its affiliates and associates, must hold from 5% to 9.9% in order for such sole holder of the Company’s Special Voting Stock to have the right to designate one (1) individual as a director on the Board of Directors of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-033314","anchor_url":"https://secwatch.observer/filing/0001104659-23-033314#claim-4655560f1f55daa709bdf50e77b1c2197a3f62d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7a8b1f005ee83610ac0314c30a6901a8d08e5e7d","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-03-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-16","outcome":"passed","proposal_text":"Approval of Amendment to the Certificate of Designation of the Company's Special Voting Stock","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"0","votes_against":"0","votes_for":"1","votes_withheld":null}]},"claim":"CYPHERPUNK TECHNOLOGIES INC. shareholders approved Approval of Amendment to the Certificate of Designation of the Company's Special Voting Stock at the 2023-03-16 meeting.","evidence_excerpt":"To consider and vote upon a proposal to amend the Certificate of Designation of Special Voting Stock of the Company as set forth in the Certificate of Amendment. 1 0 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-033314","anchor_url":"https://secwatch.observer/filing/0001104659-23-033314#claim-7a8b1f005ee83610ac0314c30a6901a8d08e5e7d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm"},{"fact_type":"material_agreement","fact_key":"50b40cda4679669d0c8c2780a89e9abbe0df87c8","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-03-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Letter Agreement","agreement_type":"other","counterparty":"BeiGene, Ltd.","effective_date":"2023-03-16","item_codes_triggered":["1.01"],"value_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. entered into Letter Agreement with BeiGene, Ltd. (effective 2023-03-16).","evidence_excerpt":"On March 16, 2023, Leap Therapeutics, Inc. (the “Company”) and BeiGene, Ltd. (“BeiGene”) entered into a letter agreement (the “Letter Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-033314","anchor_url":"https://secwatch.observer/filing/0001104659-23-033314#claim-50b40cda4679669d0c8c2780a89e9abbe0df87c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm"},{"fact_type":"governance_change","fact_key":"27f37f3da61e5ca83cccb6795014686ee1435f78","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Filed certificate of designation for Series X Non-Voting Convertible Preferred Stock, establishing rights, preferences, and limitations."},"claim":"CYPHERPUNK TECHNOLOGIES INC.: Filed certificate of designation for Series X Non-Voting Convertible Preferred Stock, establishing rights, preferences, and limitations.","evidence_excerpt":"Series X Preferred Stock On the Effective Date, Leap filed a Certificate of Designation of Preferences, Rights and Limitations of Series X Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Series X Certificate of Designation ”) in connection with the Merger.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-005803","anchor_url":"https://secwatch.observer/filing/0001104659-23-005803#claim-27f37f3da61e5ca83cccb6795014686ee1435f78","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm"},{"fact_type":"ma_transaction","fact_key":"d4520d5113e64b1f89dd18dd9b96963d472f42a1","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-01-17","consideration_text":null,"counterparty":"Flame Biosciences, Inc.","effective_date":"2023-01-17","item_codes_triggered":["2.01"]},"claim":"CYPHERPUNK TECHNOLOGIES INC. completed an acquisition involving Flame Biosciences, Inc. (closed 2023-01-17).","evidence_excerpt":"On the Effective Date, Leap completed its business combination with Flame.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-005803","anchor_url":"https://secwatch.observer/filing/0001104659-23-005803#claim-d4520d5113e64b1f89dd18dd9b96963d472f42a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm"},{"fact_type":"material_agreement","fact_key":"f1e03056d7f02d178917ae6d94477a5818cbb378","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"other","counterparty":"those stockholders of Flame that become parties","effective_date":"2023-01-23","item_codes_triggered":["1.01"],"value_text":"Registration rights for certain stockholders of Flame"},"claim":"CYPHERPUNK TECHNOLOGIES INC. entered into Registration Rights Agreement with those stockholders of Flame that become parties valued at Registration rights for certain stockholders of Flame (effective 2023-01-23).","evidence_excerpt":"At the closing of the Merger, Leap entered into a Registration Rights Agreement (the “ Registration Rights Agreement ”) with those stockholders of Flame that become parties thereto.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-005803","anchor_url":"https://secwatch.observer/filing/0001104659-23-005803#claim-f1e03056d7f02d178917ae6d94477a5818cbb378","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm"},{"fact_type":"material_agreement","fact_key":"a9bc49feaa3d426b4afe3d09ea27a1ac96f72ba2","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Support Agreements","agreement_type":"merger","counterparty":"HealthCare Ventures IX, L.P. and HealthCare Ventures VIII Liquidating Trust","effective_date":"2023-01-23","item_codes_triggered":["1.01"],"value_text":"Agreement to vote shares in favor of Merger Agreement Meeting Proposals"},"claim":"CYPHERPUNK TECHNOLOGIES INC. entered into Support Agreements with HealthCare Ventures IX, L.P. and HealthCare Ventures VIII Liquidating Trust valued at Agreement to vote shares in favor of Merger Agreement Meeting Proposals (effective 2023-01-23).","evidence_excerpt":"In connection with the execution of the Merger Agreement, Leap entered into stockholder support agreements (the “ Support Agreements ”) with each of HealthCare Ventures IX, L.P. and HealthCare Ventures VIII Liquidating Trust (the “ Stockholders ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-005803","anchor_url":"https://secwatch.observer/filing/0001104659-23-005803#claim-a9bc49feaa3d426b4afe3d09ea27a1ac96f72ba2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm"},{"fact_type":"material_agreement","fact_key":"8838b6a29eb935f361b2e187b8b3a3bc584ff18f","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"Flame","effective_date":"2023-01-23","item_codes_triggered":["1.01"],"value_text":"Merger of Leap and Flame"},"claim":"CYPHERPUNK TECHNOLOGIES INC. entered into Merger Agreement with Flame valued at Merger of Leap and Flame (effective 2023-01-23).","evidence_excerpt":"Pursuant to the Merger Agreement, Leap has\nagreed to hold a stockholders’ meeting (the “ Special Meeting ”) to submit the following matters to its stockholders","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-005803","anchor_url":"https://secwatch.observer/filing/0001104659-23-005803#claim-8838b6a29eb935f361b2e187b8b3a3bc584ff18f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm"},{"fact_type":"executive_change","fact_key":"bf5313be06","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-23","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christian Richard was appointed as Director at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"Patricia Martin and Christian Richard were appointed to the Board as directors.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-23-005803","anchor_url":"https://secwatch.observer/filing/0001104659-23-005803#claim-bf5313be06","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm"},{"fact_type":"executive_change","fact_key":"601a0d7b3d","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-23","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Patricia Martin was appointed as Director at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"Patricia Martin and Christian Richard were appointed to the Board as directors.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-23-005803","anchor_url":"https://secwatch.observer/filing/0001104659-23-005803#claim-601a0d7b3d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/0001104659-23-005803-index.htm"},{"fact_type":"earnings_release","fact_key":"251120e7e53f45b4cafcb7a9796896423d098b04","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$15.1 million","period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":null},"claim":"CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2022 results: net income $15.1 million.","evidence_excerpt":"Net Loss was $15.1 million for the third quarter 2022, compared to $11.1 million for the three months ended September 30, 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-117681","anchor_url":"https://secwatch.observer/filing/0001104659-22-117681#claim-251120e7e53f45b4cafcb7a9796896423d098b04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/0001104659-22-117681-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d2e24e48dd9536f6a6ea6319eae0e9222dfacca2","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2022-11-07T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-05-01","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2022-11-02","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)"],"rules_cited_in_text":true},"claim":"CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"November 2, 2022, Leap Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department\n(the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive\nbusiness days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued\ninclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The\nnotification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nas","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-114996","anchor_url":"https://secwatch.observer/filing/0001104659-22-114996#claim-d2e24e48dd9536f6a6ea6319eae0e9222dfacca2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922114996/0001104659-22-114996-index.htm"},{"fact_type":"executive_change","fact_key":"1b83e1d2f9","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2022-09-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-01","interim":false,"role":"Class I director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Richard Schilsky was appointed as Class I director at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"On September 1, 2022, the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) appointed Richard Schilsky, M.D. as a Class I director of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-098035","anchor_url":"https://secwatch.observer/filing/0001104659-22-098035#claim-1b83e1d2f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/0001104659-22-098035-index.htm"},{"fact_type":"executive_change","fact_key":"63d1ea0d0a","cik":1509745,"ticker":"CYPH","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2022-08-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-08-12","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Monica Bertagnolli resigned as director at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"On August 11, 2022, Dr. Monica Bertagnolli, a director of the Company, informed the Company that she will be resigning as a director, effective August 12, 2022, as a result of her appointment as the 16th Director of the National Cancer Institute (NCI) by the Biden administration.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-22-089676","anchor_url":"https://secwatch.observer/filing/0001104659-22-089676#claim-63d1ea0d0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/0001104659-22-089676-index.htm"}]}